Oncology Drug Reference Sheet: Toripalimab-Tpzi The first immunotherapy agent for the treatment of nasopharyngeal carcinoma, toripalimab (Loqtorzi ™) received its U S Food and Drug Administration (FDA) approval in October 2023 Clinical trials showed an increase in overall survival rates: After three years of treatment, 64% of patients receiving toripalimab were still alive compared to 49
Toripalimab Monograph for Professionals - Drugs. com Antineoplastic agent; humanized anti-programmed-death receptor-1 (anti-PD-1) monoclonal antibody In combination with cisplatin and gemcitabine as first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC)
FDA approves toripalimab-tpzi for nasopharyngeal carcinoma On October 27, 2023, the Food and Drug Administration approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc ) with cisplatin and gemcitabine for the first-line treatment of adults with
Junshi Biosciences Announces the sNDA Approval of - GlobeNewswire Currently, there are twelve approved indications for toripalimab in the Chinese mainland: first-line treatment for unresectable or metastatic melanoma The first 10 indications have been included
Toripalimab - Drug Targets, Indications, Patents - Synapse In this phase 3 HEPATORCH study, we aimed to compare the efficacy and safety of toripalimab plus bevacizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma We did a randomised, open-label, phase 3 study in 57 hospitals across mainland China, Taiwan, and Singapore
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy . . . 17 patients with a history of psychotropic drug abuse and unable to quit or with mental disorders; (4) Use of immunosuppressive drugs within 2 weeks before the first study drug treatment, excluding topical glucocorticoids or systemic glucocorticoids not exceeding 10 mg day of prednisone or other glucocorticoids at equivalent doses
Toripalimab Evidence Journey in Cancer Care - Syenza News Early detection and chemoradiation offered hope, but advanced or recurrent cases historically lacked effective therapies—until toripalimab’s bridged this gap through a strategic evidence journey The toripalimab evidence journey began with clinical trials in Asia